文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

DESTINATION-MRL 试验主要终点分析:中危前列腺癌的 MRI 引导在线自适应 SBRT

Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-11-26

该 II 期非随机试验在 3 家机构各入组 20 例中危前列腺癌患者,评估在线自适应 MRI 引导 SBRT 中 GTV 增量照射、CTV 降量和 0 mm PTV 外扩的技术可行性。主要终点为治疗后 MRI 上累积 GTV D90%>42 Gy 的患者比例≥90%;54 例可分析患者中 46 例(85%)达到该标准,但 3 家机构中仅 2 家达标。

要点

  • 54 例可分析患者中 46 例(85%)达到累积 GTV D90%>42 Gy 的主要终点标准。
  • 分机构看,机构 1 为 10/14(71%),机构 2 和 3 均为 18/20(90%)。
  • 作者认为在缺乏 gating 策略时无法确保 GTV 和 CTV 的稳健覆盖。

核心结论

  • 在线自适应 MRI 引导 SBRT 下 GTV 增量、CTV 降量并采用 0 mm PTV 外扩的减毒放疗在 3 家机构中的 2 家可行。
  • 在缺乏 gating 策略的情况下,无法确保 GTV 和 CTV 获得稳健覆盖。

研究设计与样本

  • DESTINATION-MRL 为在 3 家不同机构开展的 3 项平行、单中心、II 期非随机试验。
  • 每家机构入组 20 例患者,均在 1.5T Unity MR-Linac 上治疗。
  • GTV 定义为多参数 MRI 上可见的肿瘤,CTV 定义为整个前列腺,前列腺内 GTV 外扩 4 mm 以覆盖勾画和病理不确定性(GTV 4 mm),CTV 不加 PTV 外扩。
  • 所有患者 CTV 接受 30 Gy/5 次,GTV 4 mm 接受等毒性增量至 45 Gy。
  • 主要终点为技术可行性,定义为治疗后 MRI 上≥90% 的患者累积 GTV D90%>42 Gy。

主要发现

  • 2023 年 5 月至 2024 年 9 月共治疗 60 例患者,其中 54 例纳入分析。
  • 46 例患者(85%)达到累积 GTV D90%>42 Gy。
  • 机构 1 有 10/14 例(71%)达到该标准,机构 2 和机构 3 均有 18/20 例(90%)达到。

关键数值与推荐

  • 技术可行性主要终点标准为治疗后 MRI 上累积 GTV D90%>42 Gy 的患者比例≥90%。
  • CTV 处方剂量为 30 Gy/5 次,GTV 4 mm 等毒性增量至 45 Gy。

临床怎么用

  • 该减毒方案在部分机构可行,但需注意机构间差异及缺乏 gating 时 GTV/CTV 覆盖不足的风险。

局限性

  • 研究为非随机、单中心平行试验设计,每家机构样本量有限。
  • 54 例可分析患者中仅 46 例达到主要终点,未能在全部 3 家机构复现可行性。
  • 作者指出在缺乏 gating 策略时无法确保 GTV 和 CTV 的稳健覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Escalating dose to the gross tumor volume (GTV) while de-escalating dose to the prostate clinical target volume (CTV) and using a 0-mm planning target volume margin can potentially minimize toxicity without compromising biochemical control in patients with intermediate-risk prostate cancer. We evaluated the technical feasibility of this approach in online adaptive magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy. METHODS AND MATERIALS: The DESTINATION-MRL trial ran as 3 parallel single-center phase 2 non-randomized trials in 3 different institutes. Each institute enrolled 20 patients who were all treated on a 1.5T Unity MR-linear accelerator (MR-Linac). The GTV was defined as tumor(s) visible on multiparametric MRI. The CTV was defined as the whole prostate. The proximal 1-2 cm of the seminal vesicles were included in the CTV at the clinician's discretion. An intraprostatic margin of 4 mm was applied to the GTV to account for delineation and pathological uncertainty (GTV 4 mm) and no planning target volume margin was applied to the CTV. All patients were treated with 30 Gy in 5 fractions to the CTV and an isotoxic boost of 45 Gy to the GTV 4 mm. The primary endpoint was technical feasibility, defined as an accumulated GTV D90% of >42 Gy on the post-treatment MRI in ≥90% of the patients. RESULTS: Between May 2023 and September 2024, 60 patients were treated, of which 54 were included for analysis. An accumulated GTV D90% of >42 Gy was reached in 46 patients (85%). Analysis per institute showed that this criterion was reached in 10 of 14 patients (71%) in institute 1 and in 18 of 20 patients (90%) in both institutes 2 and 3. CONCLUSIONS: Although toxicity-minimizing radiation therapy in online adaptive MRI-guided stereotactic body radiation therapy for prostate cancer was feasible in 2 of the 3 institutes, robust coverage of the GTV and CTV could not be assured in the absence of a gating strategy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dassen MG, Tree AC, Wiersema L, et al. Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41314554. doi:10.1016/j.ijrobp.2025.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。